Document is current
Any future updates will be listed below
-
Authors
Diebold, Matthias https://orcid.org/0000-0002-6914-9132
Gauthier, Patrick T.
Mayer, Katharina A. https://orcid.org/0000-0003-2495-790X
Mackova, Martina
Hinze, Christian
Chang, Jessica https://orcid.org/0000-0001-5039-2186
Patel, Uptal D. https://orcid.org/0000-0002-6905-6649
Schütz, Ekkehard
Jilma, Bernd
Schrezenmeier, Eva
Budde, Klemens https://orcid.org/0000-0002-7929-5942
Böhmig, Georg A. https://orcid.org/0000-0002-7600-912X
Halloran, Philip F. https://orcid.org/0000-0003-1371-1947
-
Funding
Funding for this research was provided by:
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (P500PM_214237)
- License Information
-
More Information
Article History
Received: 6 August 2024
Accepted: 10 March 2025
First Online: 29 April 2025
Competing interests
: Data for this study were generated in an investigator-initiated trial supported by Hi-Bio. P.F.H. holds shares in Transcriptome Sciences Inc. (TSI), a University of Alberta research company dedicated to developing molecular diagnostics, supported in part by a licensing agreement between TSI and Thermo Fisher Scientific, and by a research grant from Natera, Inc. P.F.H. is a consultant to Natera, Inc. and Argenx BV. G.A.B. is supported by a research grant from Human Immunology Biosciences, Inc. (HI-Bio), South San Francisco, CA, USA, and is member of the steering committee of a planned phase 3 trial evaluating felzartamab in antibody-mediated rejection (Hi-Bio). U.D.P. is an employee and shareholder of Human Immunology Biosciences, acquired by Biogen, and serves as chair for the board of directors of the Kidney Health Initiative. M.D., P.T.G., K.A.M., M.M., C.H., J.C., E.S., B.J., E.S. and K.B. declare no competing interests.
